EURURO Vol. 72 No. 6

FM3 1030

CONTENTS
e u r o p e a n u r o l o g y , vo l . 7 2 , n o . 6 , D e c emb e r 2 0 1 7
e149
861
J.M. Jones, J. Bhatt, J. Avery, A. Laupacis, K. Cowan, N.S. Basappa, J. Basiuk, C. Canil,
S. Al-Asaaed, D.Y.C. Heng, L. Wood, D. Stacey, C. Kollmannsberger, M.A.S. Jewett
Defining disease-specific research priorities in cancer can facilitate better allocation
of limited resources. Involving patients and caregivers as well as expert clinicians
in this process is of value. We undertook this approach for kidney cancer
as an example. The Kidney Cancer Research Network of Canada sponsored
a collaborative consensus-based priority-setting partnership that identified
ten research priorities in the management of kidney cancer. These are discussed
in the context of current initiatives and gaps in knowledge.
865
B. Köves, T. Cai, R. Veeratterapillay, R. Pickard, T. Seisen, T.B. Lam, C.Y. Yuan, F. Bruyere,
F. Wagenlehner, R. Bartoletti, S.E. Geerlings, A. Pilatz, B. Pradere, F. Hofmann, G. Bonkat, B. Wullt
Treatment of asymptomatic bacteriuria is not beneficial in most patient groups.
It should be treated only prior to endourological procedures and pregnancy.
However, in the latter group, more up-to-date studies are needed to confirm benefit
in modern healthcare settings.
869
M. Lardas, M. Liew, R.C. van den Bergh, M. De Santis, J. Bellmunt, T. Van den Broeck,
P. Cornford, M.G. Cumberbatch, N. Fossati, T. Gross, A.M. Henry, M. Bolla, E. Briers, S. Joniau,
T.B. Lam, M.D. Mason, N. Mottet, H.G. van der Poel, O. Rouvière, I.G. Schoots, T. Wiegel,
P.-P.M. Willemse, C.Y. Yuan, L. Bourke
This is the first systematic review comparing the impact on cancer-specific quality
of life (QoL) of different primary treatments for clinically localised prostate cancer
(PCa), using validated cancer-specific patient-reported outcome measures only.
There is robust evidence that the choice of primary treatment for localised PCa
has a distinct impact on patients’ QoL. These aspects should be discussed in detail
with patients during pretreatment counselling.
886
D.F. Penson
888
J.P. Radtke, M. Wiesenfarth, C. Kesch, M.T. Freitag, C.D. Alt, K. Celik, F. Distler, W. Roth,
K. Wieczorek, C. Stock, S. Duensing, M.C. Roethke, D. Teber, H.-P. Schlemmer, M. Hohenfellner,
D. Bonekamp, B.A. Hadaschik
Combination of European Randomised Study of Screening for Prostate Cancer risk
calculator parameters and multiparametric magnetic resonance imaging allowed
PlatinumOpinion
Brief Correspondence
Platinum Priorities
Review Articles
and Original Articles together
with the Full Length Editorials
Prostate Cancer